Nutra Pharma Corp (NPHC) Consolidated Net Income (2010 - 2026)

Nutra Pharma has disclosed Consolidated Net Income across 17 years of filings, most recently posting -$3.9 million for Q2 2026.

• In Q2 2026, Consolidated Net Income fell 1168.46% year-over-year to -$3.9 million; the TTM figure through Jun 2026 stood at -$5.4 million (down 254.99% YoY), while the FY2025 annual figure was -$1.6 million, down 59.25% from the prior year.
• Consolidated Net Income came in at -$3.9 million for Q2 2026 at Nutra Pharma, down from -$459675.0 in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $5.0 million in Q1 2022 to a low of -$3.9 million in Q2 2026.
• Average Consolidated Net Income over 5 years is -$53221.5, with a median of -$323192.5 recorded in 2023.
• Year-over-year, Consolidated Net Income jumped 200.66% in 2025 and tumbled 1168.46% in 2026.
• Over 5 years, Consolidated Net Income stood at $3.2 million in 2022, then slumped by 107.52% to -$243064.0 in 2023, then grew by 5.0% to -$230907.0 in 2024, then tumbled by 111.57% to -$488526.0 in 2025, then slumped by 708.3% to -$3.9 million in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were -$3.9 million in Q2 2026, -$459675.0 in Q1 2026, and -$488526.0 in Q4 2025.